Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4028 - Detection of microsatellite instability (MSI) in colorectal cancer samples with the automated Idylla MSI Test


11 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Colon and Rectal Cancer


Geert Maertens


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


G. Maertens, B. De Craene, E. Rondelez, K. Peeters, L. Vandenbroeck, L. Van Puymbroeck, G. Vandercruyssen, E. Sablon

Author affiliations

  • Create, Biocartis, 2800 - Mechelen/BE


Abstract 4028


Detection of microsatellite instability (MSI) is recommended for all colorectal cancer (CRC) patients. Current clinical reference methods to detect MSI stain for mismatch repair proteins or analyze frequently mutated DNA repeat regions. The Idylla MSI Test is being developed using a unique set of novel biomarkers (Zhao et al. 2014; eLife) capable of faster detection with greater specificity and selectivity compared to current methods.


To assess the suitability of the novel marker set to detect MSI status in CRC, we profiled 8 or more markers in 870 CRC samples. Several clinical sites and different ethnic groups (Afro American, Caucasian, East-Asian, Hispanic and Indian) were included to assess robustness of marker selection. Repeat length was determined on FFPE DNA by PCR followed by melting curve analysis. Two-hundred and one samples were additionally screened with a reference methodology for MSI detection (Promega MSI analysis system).


Hundred fifty-three samples (17.6%) were classified as MSI-H and 693 samples (79.7%) as MSS with the novel set of biomarkers, while 24 samples (2.8%) could not be classified. Concordance analysis was performed on 201 samples. The overall percent agreement with results available for both methods (173/201) was 93.6%. 11/173 (6.4%) were scored MSI-H for Idylla and MSS for the reference method; conversely no MSI-H cases for the reference method and MSS for Idylla were detected. 24/201 (11.9%) samples failed with the reference method, even after repeat testing, while only 8/201 (4.0%) samples failed with the Idylla methodology.


This study on a diverse set of CRC samples successfully demonstrated the validity of the novel MSI biomarkers to discriminate between MSI-H and MSS status. The Idylla MSI Test is currently under development on the most performant markers. Compatibility with the fully integrated Idylla platform will allow providing accurate and reliable results, with actionable results generated within 150 minutes from just one tumor FFPE slice (no reference sample required).

Clinical trial identification

Legal entity responsible for the study

Biocartis NV




G. Maertens, B. De Craene, E. Rondelez, K. Peeters, L. Vandenbroeck, L. Van Puymbroeck, G. Vandercruyssen, E. Sablon: Biocartis Employee.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.